New England Research & Management Inc. Acquires 310 Shares of Eli Lilly and Company (NYSE:LLY)

New England Research & Management Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,711 shares of the company’s stock after acquiring an additional 310 shares during the period. Eli Lilly and Company makes up about 1.1% of New England Research & Management Inc.’s portfolio, making the stock its 24th largest holding. New England Research & Management Inc.’s holdings in Eli Lilly and Company were worth $2,239,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. RTD Financial Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $231,000. CVA Family Office LLC lifted its holdings in shares of Eli Lilly and Company by 7.1% during the 1st quarter. CVA Family Office LLC now owns 2,905 shares of the company’s stock worth $2,399,000 after acquiring an additional 192 shares during the period. Elevation Point Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 7.3% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 4,325 shares of the company’s stock worth $3,572,000 after acquiring an additional 295 shares during the period. West Branch Capital LLC lifted its holdings in shares of Eli Lilly and Company by 11.9% during the 1st quarter. West Branch Capital LLC now owns 5,735 shares of the company’s stock worth $4,737,000 after acquiring an additional 611 shares during the period. Finally, Salem Investment Counselors Inc. lifted its holdings in shares of Eli Lilly and Company by 4.1% during the 1st quarter. Salem Investment Counselors Inc. now owns 71,443 shares of the company’s stock worth $59,006,000 after acquiring an additional 2,827 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.8%

Shares of NYSE LLY opened at $818.56 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a 50 day moving average price of $775.43 and a two-hundred day moving average price of $801.50. The stock has a market cap of $775.78 billion, a P/E ratio of 69.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the company earned $2.58 earnings per share. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analyst Ratings Changes

A number of analysts have recently weighed in on LLY shares. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, June 7th. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.